What it’s for
- Transplant immunosuppression and selected medical conditions
Sirolimus, a prescription medicine that inhibits mTOR signalling.
Purpose, evidence and practical considerations.
Its established medical uses are distinct from off-label ageing experiments. Animal lifespan findings and short human biomarker studies do not establish longer human life.
Confidence: weak
Risks include infection, mouth ulcers, impaired healing, metabolic changes and drug interactions. Prescribing information includes serious infection and malignancy warnings. Treatment requires medical supervision and monitoring; an intermittent personal schedule is not proven safe.
Sirolimus inhibits mTOR signalling and suppresses immune-cell proliferation. Animal lifespan effects do not establish a safe or effective ageing regimen for humans.
Regulatory status: prescription medication (immunosuppressant / mTOR inhibitor), used off-label for longevity
How people use it, with their schedules, context and original sources.
Dose unconfirmed · Weekly
mTOR inhibitor — caloric restriction mimetic (recent addition)
previously taken experimentally for longevity; stopped after mouth sores
Dose and schedule patterns reported in public protocols; these are observations, not prescribing advice. Private and hidden usage is excluded.
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.